• Community Counts
  Explore health issues, medical complications, and causes of death that affect people with bleeding disorders who receive care at U.S. Hemophilia Treatment Centers
• Basics About Hemophilia
  
• What is an inhibitor?
  All people with hemophilia and VWD type 3 are at risk for developing an inhibitor ? an antibody ? to treatment used to stop or to prevent a bleeding episode: Anthony's story.
• Hemophilia Treatment Center (HTC) Directory
  
• Making Strides Toward Preventing Inhibitors in Bleeding Disorders
  
• World Hemophilia Day 2016
  
• Key Findings: Study of Hemophilia Care Outcomes over 50 Year Span Reveals Progress, Ongoing Health Challenges
  
• The safety of blood products is important for people with hemophilia
  
• Hemophilia and maintaining a healthy weight
  
• Many people with hemophilia will develop an inhibitor
  
• CDC information on hemophilia
  
• CDC Information: Do You Have Hemophilia and an Inhibitor?
  

Go to CDC Information Database

• Prophylaxis use among males with haemophilia B in the United States.
  Ullman M et al. Haemophilia : the official journal of the World Federation of Hemophilia 2017 Nov 23(6) 910-917
• The effects of joint disease, inhibitors and other complications on health-related quality of life among males with severe haemophilia A in the United States.
  Soucie J M et al. Haemophilia : the official journal of the World Federation of Hemophilia 2017 Jul 23(4) e287-e293
• Accounting for differences in healthcare utilization and expenditures among US males with haemophilia by type of health insurance.
  Guh S et al. Haemophilia : the official journal of the World Federation of Hemophilia 2017 23(2) e147-e151
• Achievements, challenges and unmet needs for haemophilia patients with inhibitors: Report from a symposium in Paris, France on 20 November 2014.
  Dargaud Y et al. Haemophilia : the official journal of the World Federation of Hemophilia 2016 Jan 22 Suppl 11-24
• Game, set, match for factor VIII mismatch?
  Miller Connie H et al. Blood 2015 Aug 13. 126(7) 829-30
• Evaluation of von Willebrand factor phenotypes and genotypes in Hemophilia A patients with and without identified F8 mutations.
  Boylan B et al. J. Thromb. Haemost. 2015 Jun 13(6) 1036-42
• Estimates of utility weights in hemophilia: implications for cost-utility analysis of clotting factor prophylaxis.
  Grosse Scott D et al. Expert review of pharmacoeconomics & outcomes research 2015 Apr 15(2) 267-83
• The CDC Hemophilia B mutation project mutation list: a new online resource.
  Li Tengguo et al. Mol Genet Genomic Med 2013 Nov 1(4) 238-45
• Mutation analysis of a cohort of US patients with hemophilia B.
  Li Tengguo et al. Am. J. Hematol. 2014 Apr 89(4) 375-9
• The CDC Hemophilia A Mutation Project (CHAMP) mutation list: a new online resource.
  Payne Amanda B et al. Hum. Mutat. 2013 Feb 34(2) E2382-91
• Utility of multiplex ligation-dependent probe amplification (MLPA) for hemophilia mutation screening.
  Payne A B et al. J. Thromb. Haemost. 2012 Sep 10(9) 1951-4
• F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis.
  Gouw Samantha C et al. Blood 2012 Mar 22. 119(12) 2922-34
• Health care expenditures for Medicaid-covered males with haemophilia in the United States, 2008.
  Guh S et al. Haemophilia : the official journal of the World Federation of Hemophilia 2012 Mar 18(2) 276-83
• Healthcare expenditures for males with haemophilia and employer-sponsored insurance in the United States, 2008.
  Guh S et al. Haemophilia : the official journal of the World Federation of Hemophilia 2012 Mar 18(2) 268-75
• F8 and F9 mutations in US haemophilia patients: correlation with history of inhibitor and race/ethnicity.
  Miller C H et al. Haemophilia 2012 May 18(3) 375-82

Go to CDC-Authored Genomics Publication Database

Get Records

Get Records

Get Records

Get Records

Get Records

Get Records

Get Records

Get Records

Get Records

• Acquired hemophilia
  From NCATS Genetic and Rare Diseases Information Center
• Acquired hemophilia A
  From NCATS Genetic and Rare Diseases Information Center
• Factor VIII Inhibitors: Generating a National Blueprint for Future Research
  NHLBI Conference, May 15-18, 2018
• Hemophilia
  From NHLBI health topic site
• Hemophilia
  From NCATS Genetic and Rare Diseases Information Center
• Hemophilia A
  From NCATS Genetic and Rare Diseases Information Center
• Hemophilia B
  From NCATS Genetic and Rare Diseases Information Center
• Von Willebrand Disease
  From NHLBI health topic site

Get Records

The Genetic Testing Registry (GTR®) provides a central location for voluntary submission of genetic test information by providers. The scope includes the test's purpose, methodology, validity, evidence of the test's usefulness, and laboratory contacts and credentials. The overarching goal of the GTR is to advance the public health and research into the genetic basis of health and disease.

• Search the Genetic Testing Registry for "Hemophilia"

OMIM is a comprehensive, authoritative compendium of human genes and genetic phenotypes that is freely available and updated daily.

• Search OMIM for "Hemophilia"

PubMed Clinical Queries is an utility offered by PubMed to search scientific literature in specific clinical research areas

• Search PubMed Clinical Queries for "Hemophilia"

The PharmGKB is a pharmacogenomics knowledge resource that encompasses clinical information including dosing guidelines and drug labels, potentially clinically actionable gene-drug associations and genotype-phenotype relationships.

• Search PharmGKB for "Hemophilia"

PubMed comprises more than 27 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.

• PubMed links to genetics reviews articles for "Hemophilia"